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Background: The Aptima HPV assay (AHPV) for high-risk human papillomavirus (hrHPV), and the Aptima
HPV 16 18/45 Genotype assay (AHPV GT) for HPV16 and for HPV18 and/or HPV45 (HPV18/45) genotypes
are approved for cervical cancer screening by the U.S. Food and Drug Administration. There are limited
data on the reliability of these tests for detection of hrHPV, HPV16, and HPV18/45.
Objectives: To assess the reliability of AHPV and AHPVGT on paired specimens fromwomenwith atypical
squamous cells of undetermined signiﬁcance (ASC-US) cytology.
Study design: In a population ofwomenwithASC-US cytology (n=988), cervical specimenswere collected
at a routine screening baseline visit and at the colposcopy visit that occurred a median of 29 days later.
Specimens were tested by AHPV and if positive, by AHPV GT.
Results: There was no signiﬁcant difference in the percent AHPV positive between the colposcopy and
baseline specimens (41.9% vs. 43.0%, respectively, p=0.3). The percent agreement, percent positive
agreement, and the kappa value were 88.6%, 76.3%, and 0.766, respectively. There were no signiﬁcant
differences between AHPV testing of the colposcopy and baseline specimen in the sensitivity (95.2% vs.
92.9%, respectively, p=1) and speciﬁcity (60.5% vs. 59.2%, respectively, p=0.3) for CIN3+. Comparing the
hierarchical AHPV and AHPV GT results on the two specimens, the percent exact agreement was 86.2%,
the percent positive agreement was 68.4%, and the kappa value was 0.746.
Conclusions:AHPV andAHPVGTdemonstrated good reliability for hrHPVdetection and risk stratiﬁcation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Background
High-risk human papillomavirus (hrHPV) testing is now recom-
mended for use in the U.S. with cytology (“cotesting”) for cervical
cancer screening every 5 years in women aged 30–64 years of age,
[1] for triage of an equivocal Pap result, [2] and for follow-up of
womenwhounderwent colposcopy and treatment for cervical pre-
cancerous lesions (cervical intraepithelial neoplasia grade 2 (CIN2),
grade 3 (CIN3), and adenocarcinoma in situ (AIS) [2]. The World
Health Organization recently recommended hrHPV testing as an
alternative to Pap/cytology screening where Pap/cytology has not
been successfully implemented [3].
Clinical sensitivity for CIN2 ormore severe (CIN2+) and test reli-
ability are key requirements of hrHPV testing [4,5]. The Aptima
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HPV assay (AHPV; Hologic, Bedford, MA, USA), a qualitative test
for E6/E7 RNA for a pool of 14 hrHPV genotypes, is one of 4 hrHPV
tests that are currently approved by the U.S. Food and Drug Admin-
istration (U.S. FDA). In a number of studies, AHPVhas demonstrated
high sensitivity for CIN2+ and a speciﬁcity that is better than other
tests that detect hrHPVDNA [6–10]. TheU.S. FDA-approvedAptima
HPV 16 18/45 Genotype assay (AHPV GT) is a triage genotyping
test for the detection of HPV16 individually and HPV18 and HPV45
(HPV18/45) together.
2. Objectives
There are limited data on the reproducibility of AHPV and AHPV
GT. One previous study of AHPV reported excellent intra- and
inter-laboratory kappa values of 0.89 and 0.91, respectively [6].
However, there are no data on the reproducibility of AHPV GT.
To address this gap, data from the CLEAR [Clinical Evaluation of
APTIMA mRNA] trial [11] were used. Women with atypical squa-
mous cells of undetermined signiﬁcance (ASC-US) cytology were
enrolled, and specimens collected at baseline and at the colposcopy
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visit were tested with the AHPV and AHPV GT assays, permitting
an evaluation of their reliability for detection of hrHPV and risk
stratiﬁcation by HPV genotyping.
3. Study design
3.1. Study procedures
Women who participated in this study were part of the CLEAR
study, a pivotal, prospective, multicenter U.S. clinical study for
the triage of women with ASC-US cytology for colposcopy refer-
ral. The median, mean, and range of age were 30, 32.6, and 17–71
years, respectively. Eligible women invited to participate were 21
years or older who were undergoing routine Pap testing, and who
had an ASC-US cytology result. Women were recruited from 19
U.S. family planning and obstetric/gynecologic clinics (private and
academic), family practice medical groups, and clinical research
centers encompassing awide geographic area representative of the
US population.
ThinPrep specimens were collected from women at the routine
screening baseline visit as described previously (11), with testing
conducted for cytology, hrHPV DNA (Hybrid Capture 2, HC2, Qia-
gen Inc.) and hrHPV RNA (AHPV). In addition, ThinPrep specimens
were also collected from 988 women sent to colposcopy due to
an ASC-US cervical cytology result. The mean, median, and range
of time between baseline screening visit and colposcopic referral
were33.7, 29, and7–275days, respectively. TheThinPrep specimen
collected at colposcopy was sent to Hologic. Samples were stored
for up to 21 months at 4 ◦C before aliquoting and freezing.
For each subject in the study, an endocervical curettage spec-
imen and punch biopsies (directed biopsy if visible lesions were
present, random biopsy from each of 4 quadrants if no lesion was
present) were obtained and reviewed by up to 3 expert patholo-
gists, and the consensusdiagnosiswasused fordeterminingdisease
status.
3.2. hrHPV testing
AHPV and AHPV GT testing of both the baseline and colposcopy
specimens were performed according to the manufacturer’s
instructions using the Tigris DTS system. Three clinical laborato-
ries each tested approximately one-third of all baseline specimens
with AHPV and AHPV GT. The colposcopy specimens were tested
with AHPV and AHPV GT at Hologic (San Diego, CA). hrHPV DNA
testing of the baseline specimen using HC 2 was performed by the
local institutional laboratory for each enrollment site or at a central
laboratory (LabCorp, Burlington, NC). hrHPVDNA testing of the col-
poscopy specimens using the cobas 4800 systemwas performed at
LabCorp according to the manufacturer’s instructions. A specimen
was considered test positive for hrHPV by cobas if any of the three
cobas channels (other 12 hrHPV, HPV16, or HPV18) was positive.
Operators performing hrHPV testing were blind to all test results.
AHPV and AHPV GT results were combined to create hierarchi-
cal HPV categories based on cancer risk: HPV16 and/or HPV18/45
(HPV16/18/45) positive, elseHPV16/18/45negativebuthrHPVpos-
itive, else hrHPV negative.
3.3. Pathology
Cervical disease statuswas based on biopsy samples collected at
the colposcopy visit. As previously described in detail [11], biopsies
were processed and reviewed locally and then underwent a con-
sensus panel reviewprocess inwhich the diagnosiswas assigned to
a category in the3-tieredCIN terminology. The consensusdiagnosis
was used in these analyses.
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Fig. 1. Correlation of signal strength for Aptima HPV (AHPV) assay results on spec-
imens collected at baseline and colposcopy. The dotted line indicates the positive
cutpoint. The solid line indicates equal signal strength. , Spearman correlation.
3.4. Statistical analyses
Signal strengths forAHPV testingpaired specimens inwhichone
or more was positive were compared by calculating the Spearman
correlation and tested for differences using a sign rank test. Percent
agreement between assays is calculated as the number in which
both tests are positive divided by the number of positives by either
or both assays. Categorical paired results for AHPV and AHPV GT
were compared using percent agreement, percent positive agree-
ment, and kappa values and tested for differences using an exact
version of a McNemar’s chi square (2 categories) or symmetry chi
square (>2 categories) tests. Sensitivity and speciﬁcity with 95%
conﬁdence intervals (95% CI) for CIN2 or more severe diagnoses
(CIN2+) or CIN3+ were calculated for AHPV testing on both spec-
imens and differences were tested for signiﬁcance using an exact
version of a McNemar’s chi square test. Stata version 12.1 (Stata
Corporation, College Station, TX, USA) was used for most analyses.
4. Results
A scatterplot of the assay signal strength for AHPV testing of the
paired baseline and colposcopy specimens is shown in Fig. 1Among
AHPV results onpaired specimen inwhichoneor bothwaspositive,
the spearman correlation was 0.602 and there was no statistical
difference in the signal strength (p=0.3).
Table 1 shows the AHPV results on the baseline and colposcopy
specimens, overall and stratiﬁed by ﬁnal histology diagnosis;
hrHPV testing by HC2 of the baseline specimen; hrHPV test-
ing by cobas of the colposcopy specimen; and the median time
between the specimen collections (median=29 days, mean=33.7
days, range=7–275 days). Overall, there was no signiﬁcant differ-
ence in the percent AHPV positive between the colposcopy and
baseline specimens (41.9% vs. 43.0%, respectively, p=0.3). The per-
cent agreement, percent positive agreement, and the kappa value
were 88.6%, 76.3%, and 0.766, respectively. Therewas no signiﬁcant
difference in the AHPV positivity for the baseline vs. the colposcopy
specimen stratiﬁed by diagnosis or by time between specimen col-
lections. Importantly, the overall andpositive agreements for AHPV
between the two sample types among subjects with CIN2 or more
severe diagnosis were consistently high, >92%.
When AHPV results were stratiﬁed by other hrHPV testing
results (by HC2 on the baseline specimen or by cobas on the
colposcopy specimen; “independent hrHPV test”), the positive
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Table 1
Percent positive, paired results, and agreement statistics (percent (%) agreement, percent (%) positive agreement, and kappa) for high-risk human papillomavirus (hrHPV)
detection by Aptima HPV (AHPV) on specimens collected at baseline and at colposcopy from women with an atypical squamous cell of undetermined signiﬁcance (ASC-US).
Results are presented for all women and stratiﬁed by diagnosis, other HPV tests, and time between baseline and colposcopy visits. Differences in percent positive were tested
for statistical signiﬁcance using an exact version of McNemar chi-square test.
Colposcopy Pos — Pos Pos Neg Neg N % Agreement %Positive agreement Kappa p
Baseline — Pos Pos Neg Pos Neg Total
All N 414 425 363 51 62 512 988 88.6% 76.3% 0.766 0.3
%row 41.9% 43.0% 36.7% 5.2% 6.3% 51.8%
CIN3a N 40 39 38 2 1 1 42 92.9% 92.7% 0.3636 1
%row 95.2% 92.9% 90.5% 4.8% 2.4% 2.4%
CIN2 N 44 43 42 2 1 7 52 94.2% 93.3% 0.7892 1
%row 84.6% 82.7% 80.8% 3.8% 1.9% 13.5%
CIN2+ N 84 82 80 4 2 8 94 93.6% 93.0% 0.6915 0.7
%row 89.4% 87.2% 85.1% 4.3% 2.1% 8.5%
<CIN2 N 330 343 283 47 60 504 894 88.0% 72.6% 0.7451 0.2
%row 36.9% 38.4% 31.7% 5.3% 6.7% 56.4%
Cobas positivea N 386 374 346 40 28 34 448 84.8% 83.6% 0.4113 0.2
%row 86.2% 83.5% 77.2% 8.9% 6.3% 7.6%
Cobas negativea N 28 51 17 11 34 478 540 91.7% 27.4% 0.390 0.0008
%row 5.2% 9.4% 3.1% 2.0% 6.3% 88.5%
hc2 Positiveb N 368 387 335 33 52 47 467 81.8% 79.8% 0.4141 0.05
%row 78.8% 82.9% 71.7% 7.1% 11.1% 10.1%
hc2 Negativec N 18 10 5 13 5 431 454 96.0% 21.7% 0.3384 0.1
%row 4.0% 2.2% 1.1% 2.9% 1.1% 94.9%
<29 Daysd N 208 218 187 21 31 240 479 89.1% 78.2% 0.780 0.2
%row 43.4% 45.5% 39.0% 4.4% 6.5% 50.1%
≥29 Daysd N 206 207 176 30 31 272 509 88.0% 74.3% 0.7515 1
%row 40.5% 40.7% 34.6% 5.9% 6.1% 53.4%
Abbreviations: CIN3, cervical intraepithelial neoplasia grade 3; CIN2, cervical intraepithelial neoplasia grade 2; pos, positive; neg, negative; %row, row percentage.
a Includes one diagnosis of adenocarcinoma in situ.
b Testing done on specimens collected at colposcopy.
c Testing done on specimens collected at baseline; 67 results were missing.
d Time between clinical visits and the collection of specimens.
Table 2
Sensitivity, speciﬁcity, and positive (PPV) and negative (NPV) predictive valueswith
95% conﬁdence intervals (95% CI) for diagnoses of cervical intraepithelial grade 2 or
more severe diagnoses (CIN2+) and cervical intraepithelial grade 3 or more severe
diagnoses (CIN3+) for high-risk humanpapillomavirus (hrHPV) detection byAptima
HPV (AHPV)doneon specimens collected at colposcopy andat baseline fromwomen
with an atypical squamous cell of undetermined signiﬁcance (ASC-US). Differences
in sensitivity and speciﬁcity were tested for statistical signiﬁcance using an exact
version of McNemar chi-square test. LL, UL: lower and upper limits of 95% CI.
AHPV (colposcopy) AHPV (baseline)
Value LL UL Value LL UL p
Endpoint =CIN2+a
Sensitivity 89.40% 81.30% 94.80% 87.20% 78.80% 93.20% 0.7
Speciﬁcity 63.10% 59.80% 66.30% 61.60% 58.40% 64.80% 0.2
Endpoint =CIN3a
Sensitivity 95.20% 83.80% 99.40% 92.90% 80.50% 98.50% 1
Speciﬁcity 60.50% 57.30% 63.60% 59.20% 56.00% 62.30% 0.3
a Includes 1 case of CIN3/adenocarcinoma in situ.
agreementwasmuch lower amonghrHPVnegatives than byhrHPV
positives by the independent third test. The results from the inde-
pendent hrHPV tests were slightly better correlatedwith the AHPV
result when it was done on the same specimen than between the
AHPV tests, or between AHPV and an independent hrHPV test done
on different specimens: the kappa value for AHPV and HC2 on the
baseline specimenwas0.805, forAHPVandcobason thecolposcopy
specimen the kappa value was 0.815, for AHPV on the baseline
and cobas on colposcopy specimens the kappa value was 0.744,
and for AHPV on the colposcopy specimen and HC2 on the base-
line specimen the kappa value was 0.747 (data not shown). The
clinical performance of AHPV is compared in Table 2. There were
no signiﬁcant differences between AHPV testing of the colposcopy
and baseline specimen in the sensitivity (89.4% vs. 87.2%, respec-
tively, p=0.7) and speciﬁcity (63.1% vs. 61.6%, respectively, p=0.2)
for CIN2+. Similarly, for CIN3+ subjects there were no signiﬁcant
differences in AHPV sensitivity (95.2% vs. 92.9%, respectively, p=1)
and speciﬁcity (60.5% vs. 59.2%, respectively, p=0.3).
The AHPV and AHPV GT results were combined and classiﬁed
hierarchically according toHPV type cancer risk for the 907women
with both a baseline and colposcopy AHPV and HPV GT result
(Table 3): HPV16 positive, else HPV16 negative and HPV18/45 pos-
itive, else HPV16, 18, 45 negative and AHPV positive (other hrHPV
types), else AHPVnegative. The percent exact agreementwas 86.2%
(782 of 907), percent exact agreement among positives was 68.4%
(270 of 395), and the kappa was 0.746 comparing the hierarchical
AHPV and AHPVGT results on the two specimens. The percent pos-
itive agreements for HPV 16, HPV 18/45, and other hrHPV were
86.1%, 72.7%, and 77.2%, respectively. The p value for the exact
symmetry chi-square test was 0.8 (data not shown).
5. Discussion
One of the hallmarks of hrHPV testing is its reproducibility [4,5].
We demonstrated in an ASC-US Pap population that hrHPV detec-
tion and clinical performance for detection of CIN2+ and CIN3+ by
AHPV as well as HPV risk stratiﬁcation by AHPV and AHPV GTwere
reliable, even between two specimens collected one month apart
and tested by different labs. By comparison, a previous study of
repeat testing of HC2, where one testwas done by one of 4 commu-
nity labs and the second test done by a central QC lab on the same
specimen, inwomenwith ASC-US or low-grade squamous intraep-
ithelial lesion (LSIL) cytology, reported a kappa value of 0.84 [12]. In
addition, a previous report on the reproducibility of AHPV testing
of 546 specimens found the intra-laboratory and inter-laboratory
kappa values to be 0.89 and 0.91, respectively.
The lower kappa value reported in this study, 0.77, may be
the result of the variability introduced by testing two different
specimens, rather than testing the same sample twice as done
previously. The slightly albeit non-signiﬁcantly better correla-
tion between AHPV results among the specimens collected within
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Table 3
Agreement of test results for Aptima high-risk human papillomavirus (hrHPV) testing (AHPV) and HPV genotype (GT) testing (AHPV GT) of AHPV positives for HPV16 and
HPV18/45 done on specimens collected at baseline and at the time of colposcopy. Results were ranked hierarchically according to cancer risk: HPV16 positive, else HPV16
negative and HPV18/45 positive, else HPV16 and HPV18/45 negative but hrHPV positive (“other hrHPV), or else AHPV negative (Neg). Eighty-one baseline hrHPV-positive
specimens were not tested for HPV genotypes and were excluded from this analysis. Gray-highlighted cells indicate exact agreement.
AHPV (Colposcopy)
HPV16 HPV18/45 Other hrHPV Neg Total
AHPV (baseline) HPV16 n 62 1 6 3 72
row% 86.1% 1.4% 8.3% 4.2% 100%
% of Total 6.8% 0.1% 0.7% 0.3% 7.9%
HPV18/45 n 0 32 7 5 44
row% 0.0% 72.7% 15.9% 11.4% 100%
% of Total 0.0% 3.5% 0.8% 0.6% 4.9%
Other hrHPV n 5 5 176 42 228
row% 2.2% 2.2% 77.2% 18.4% 100%
% of Total 0.6% 0.6% 19.4% 4.6% 25.1%
Neg n 7 5 39 512 563
row% 1.2% 0.9% 6.9% 90.9% 100%
% of Total 0.8% 0.6% 4.3% 56.4% 62.1%
Total n 74 43 228 562 907
% of Total 8.2% 4.7% 25.1% 62.0% 100%
29 days (vs. 29 or more) and between AHPV results and hrHPV
DNA testing results on the same specimen (vs. different speci-
mens by AHPV) support this possibility. Even in a short period
of time, some hrHPV infections possibly cleared while new infec-
tions were acquired, contributing to the discordance between
AHPV tests on specimens collected at different times [13]. Indeed,
discordance in this analysis includes both inter-laboratory and
inter-specimen contributions, which again represent confounding
factors not encountered in the previous studies.
In conclusion, the clinical performance results previously
reported [11] and the reliability of AHPV and AHPV GT shown in
this analysis support their use in cervical cancer screening in gen-
eral, and speciﬁcally in the management of women with ASC-US.
Importantly, AHPVGT reliably detectsHPV16andHPV18/45,which
may be useful in risk stratifying women who test hrHPV positive
and Pap negative in routine screening [1].
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